Chardan Capital Has Lowered Expectations for uniQure (NASDAQ:QURE) Stock Price

uniQure (NASDAQ:QURE) had its price target dropped by Chardan Capital from $38.00 to $35.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the biotechnology company’s stock. Chardan Capital’s price target indicates a potential upside of 142.05% from the company’s previous close.

Other research analysts have also recently issued research reports about the stock. Guggenheim reiterated a “buy” rating and set a $28.00 price target on shares of uniQure in a report on Monday, May 12th. Wall Street Zen cut shares of uniQure from a “hold” rating to a “sell” rating in a report on Saturday, June 14th. HC Wainwright reiterated a “buy” rating and set a $70.00 price target on shares of uniQure in a report on Thursday, May 29th. Finally, Cantor Fitzgerald upgraded shares of uniQure to a “strong-buy” rating in a report on Monday, May 19th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $37.55.

uniQure Price Performance

Shares of QURE opened at $14.46 on Tuesday. uniQure has a 1-year low of $4.45 and a 1-year high of $19.18. The stock has a market cap of $792.12 million, a PE ratio of -3.69 and a beta of 0.08. The firm has a 50-day simple moving average of $14.89 and a two-hundred day simple moving average of $13.68. The company has a debt-to-equity ratio of 1.53, a current ratio of 9.98 and a quick ratio of 11.99.

uniQure (NASDAQ:QURE) last announced its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported ($0.69) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.20. The firm had revenue of $5.26 million during the quarter, compared to analysts’ expectations of $5.00 million. uniQure had a negative net margin of 1,387.98% and a negative return on equity of 1,010.74%. As a group, analysts forecast that uniQure will post -3.75 EPS for the current year.

Insider Activity at uniQure

In related news, Director Jack Kaye sold 2,112 shares of the firm’s stock in a transaction that occurred on Friday, June 20th. The shares were sold at an average price of $14.45, for a total value of $30,518.40. Following the sale, the director directly owned 20,439 shares of the company’s stock, valued at approximately $295,343.55. This trade represents a 9.37% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director David D. Meek sold 2,112 shares of the firm’s stock in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $14.45, for a total transaction of $30,518.40. Following the completion of the sale, the director directly owned 34,190 shares in the company, valued at $494,045.50. This represents a 5.82% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 22,144 shares of company stock worth $322,426 over the last three months. Company insiders own 4.79% of the company’s stock.

Institutional Investors Weigh In On uniQure

Several hedge funds have recently modified their holdings of the stock. Aberdeen Group plc increased its position in shares of uniQure by 24.2% in the second quarter. Aberdeen Group plc now owns 2,750,714 shares of the biotechnology company’s stock worth $38,345,000 after acquiring an additional 535,163 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new position in uniQure during the 2nd quarter worth approximately $117,000. Woodline Partners LP lifted its position in uniQure by 25.0% during the 1st quarter. Woodline Partners LP now owns 175,806 shares of the biotechnology company’s stock worth $1,864,000 after acquiring an additional 35,175 shares in the last quarter. 683 Capital Management LLC lifted its position in uniQure by 1.6% during the 1st quarter. 683 Capital Management LLC now owns 1,550,000 shares of the biotechnology company’s stock worth $16,430,000 after acquiring an additional 25,000 shares in the last quarter. Finally, Vestal Point Capital LP raised its stake in shares of uniQure by 58.4% during the first quarter. Vestal Point Capital LP now owns 4,792,572 shares of the biotechnology company’s stock valued at $50,801,000 after purchasing an additional 1,767,572 shares during the period. 78.83% of the stock is owned by institutional investors and hedge funds.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.